Multiplexing Prism for Monocular Vision

Overseen By Eli Peli, OD

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: Massachusetts Eye and Ear Infirmary

Disqualifiers: Cognitive dysfunction, Balance problems, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

Duration: 2-3 weeks

30 Participants Needed

Trial Summary

What is the purpose of this trial?

The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye). The investigators are testing a simplified design and fitting protocol to provide field expansion for individuals with acquired monocular vision.

Research Team

Eli Peli, OD

Principal Investigator

Schepens Eye Research Institute

Eligibility Criteria

This trial is for people who have lost vision in one eye for more than a year, but still have good vision (better than 20/32) in their other eye without any field defects. They should not have health issues like seizures or motor movement problems.

Inclusion Criteria

I have been blind in one eye for more than a year.

I do not have seizures or problems with motor movements.

Your vision in the seeing eye is better than 20/32 even with corrective lenses.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are fitted with the multiplexing prism to expand the field of view

2-3 weeks

2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Multiplexing Prism

Trial Overview The study is testing a device called a multiplexing prism designed to widen the visual field for those with sight in only one eye. The focus is on evaluating a new simplified design and how easy it is to fit this device to help with vision.

Participant Groups

Group I: Field Expansion Experimental Treatment 1 Intervention

Field of view on the nasal side (same side as the blind eye) with and without multiplexing prism

Who Is Running the Clinical Trial?

Massachusetts Eye and Ear Infirmary

Lead Sponsor

Trials

115

Recruited

15,000+

National Eye Institute (NEI)

Collaborator

Trials

572

Recruited

1,320,000+